THE TAPE
KYMR · Biotechnology · $10.7B

Kymera Therapeutics, Inc. Common Stock

$125.85▼ −1.35%
Last close
Relative strength
94RS
of 99, against every stock▲ +13 on the month
Powering up
Developing
+28.6%
six months against Biotechnology
52-week range
−11.9%
from the high
$62.13$142.92
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth WEAKProof PENDING
Quarter to Sep 30, revenue −100% on a year ago
Why it is on no screen

KYMR passes every check below but is not on a screen — the screens also require the base to be the most recent structure, which this one is not.

A base has formed15.8 weeks, from 69.48 to 95.90.
Long enough to count15.8 weeks against 3 needed.
Shallow enough27.5% deep against 35% allowed.
Close to its pivot+31.2% from the pivot; listed down to -20%.
Relative strengthRS 94 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$121.86
-3.2% · tested 8× · last 7 sessions ago
Resistance above
$128.42
+2.0% · tested 3× · last 58 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Kymera Therapeutics, Inc. Common Stock is not on any of the screens right now. Its relative strength rating is 94, and it sits in Biotechnology.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+16.8%
Three months against its industry
+10.6%
Six months against its industry
+28.6%

Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 3.1% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$102.2M
-100.0% year on year
Operating margin
-396.0%
Net margin
267.3%
Free cash flow
$-288.9M
-2.7% of market cap
Price to sales
105.1×
Price to earnings
39.3×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 29
Key takeaway
Shrinking and burning cash: the quarter weakens the case.
Revenue
—
-100.0% QoQ · -100.0% YoY
Gross margin
—
Net income
−$132.0M
Loss
Free cash flow
−$78.2M
Burning · 5q runway

What the numbers say

  • Weak: Revenue -100.0% year over year, -100.0% on the quarter
  • Weak: Net loss $132M, wider than $61M last quarter
  • Weak: Burning cash: operating cash flow -$78M, free cash flow -$78M, worse than -$55M last quarter · 5 quarters of cash at this burn
  • Weak: Growth externally funded: capex $315K against operating cash flow -$78M; share count +14.7% in a year
  • Good: Net cash $373M · cash $373M
Revenue by quarter
Free cash flow
Net income
shares +14.7% in a year · net cash $373.4M

What is not obvious

  • Weak: Stock compensation $19M added back against negative operating cash flow
Final read
Growth: WEAK · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is revenue growth: revenue -100.0% year over year, -100.0% on the quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-13
-5.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Pulled back while its group leadsTape · 2026-11-13
3 lower closes in a leading group, 50d held, at 127.17
Mixed: stocks have lagged random stocks by 1.0% over three sessions, not consistently enough to call (433 cases over 59 nights). Against their own sector they have lagged by 0.9%.
GappedTape · 2026-11-10
+5.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-06
-6.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
New 52-week highTape · 2026-11-05
2.1x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
GappedTape · 2026-11-05
+7.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Unusual volumeTape · 2026-11-05
3.3 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-10-31
above 20d & 50d on 1.9x volume at 126.63
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
160
$391,444,797 total

Sold: Mainolfi Nello, Adams Brian, Goodman Noah, Jacobs Bruce N., Booth Bruce, BVF PARTNERS L P/IL, Chadwick Jeremy G.

Not counted above: 9 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-01 Mainolfi Nello · Chief Executive Officer, Directoroption exercise30,000$62,400
2026-10-01 Mainolfi Nello · Chief Executive Officer, Directorsell3,525$392,826
2026-10-01 Mainolfi Nello · Chief Executive Officer, Directorsell5,506$618,985
2026-10-01 Mainolfi Nello · Chief Executive Officer, Directorsell4,876$552,158
2026-10-01 Mainolfi Nello · Chief Executive Officer, Directorsell7,601$869,782
2026-10-01 Mainolfi Nello · Chief Executive Officer, Directorsell8,230$949,742
2026-10-01 Mainolfi Nello · Chief Executive Officer, Directorsell262$30,423
2026-09-04 Adams Brian · Chief Legal Officersell1,209$139,700

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy5
Buy17
Hold2
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Kymera Therapeutics, Inc. Common Stock (KYMR) — The Tape